Pj. Garvin et al., EXOCRINE EFFECTS OF THE CCK ANTAGONIST L-364,718 IN CANINE PANCREATICAUTOGRAFTS, The Journal of surgical research, 61(1), 1996, pp. 256-259
This study evaluated the effect of the cholecystokinin antagonist L364
,718 on exocrine secretion in canine pancreatic autografts with pancre
aticocystostomies. Urinary (autograft) amylase (U/min) and bicarbonate
(mmole/min) secretion, over a 6 hr interval, were determined in the b
asal state (Group A), after a bolus injection of 20 nmoles/kg of L-364
,718 (Group B), during a continuous cholecystokinin octapeptide (OP-CC
K) infusion at 125 ng/kg/hr either alone (Group C), with a bolus injec
tion of 20 nmoles/kg (Group D), or 30 nmoles/kg (Group E), of L-364,71
8 1 hr before initiating OP-CCK, or 20 nmoles/kg of L-364,718 1 hr aft
er initiating OP-CCK (Group F). L-364,718 had no effect on basal or OP
-CCK-stimulated secretion of bicarbonate. Basal amylase secretion was
decreased 1 hr after L-364,718 and remained significantly lower than c
ontrols throughout the study interval. When compared to Group C (280.3
+/- 48.6), OP-CCK-stimulated amylase secretion was significantly lowe
r for the first hour after L-364,718 in both Group D (157 +/- 46.7) an
d Group E (31.9 +/- 11.6). In Group E, 2, 3, and 4 hr post-L-364,718 a
mylase releases were 60.2 +/- 19.7, 77.7 +/- 25.1, and 87.2 +/- 28.3 c
ompared to 335.5 +/- 85.9, 291.0 + 21.8, and 289.9 +/- 45.7 in Group C
indicating a sustained significant inhibition of stimulated autograft
amylase secretion with the higher L-364,718 dosage. In Group F, no si
gnificant change in amylase secretion was demonstrated, indicating tha
t L-364,718 must be administered prior to CCK stimulation to be effect
ive. These studies demonstrate that L-364,718 has a dose dependent, in
hibitory effect on basal, and OP-CCK-stimulated amylase secretion in a
denervated autograft model. The therapeutic potential of L-364,718 an
d other CCK receptor antagonists in pancreatic transplantation warrant
s further study. (C) 1996 Academic Press, lnc.